{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:52:01Z","timestamp":1789145521687,"version":"build-2803163510"},"reference-count":39,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The financial strain of type 1 diabetes on the United States health care system, patients, and employers underscores the importance of developing novel treatments for the disease. This study estimated the lifetime economic burden attributable to type 1 diabetes in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A patient-level, Markov state\/transition simulation model was developed to compare cumulative societal costs among patients with and without type 1 diabetes. For each patient type, 1 prevalent and 10 incident cohorts were constructed and followed annually over a lifetime horizon. The 1 prevalent cohort with type 1 diabetes entered in the first year of the model and at the current age of each patient, whereas the 10 incident cohorts entered in each of 10 subsequent years and at the age of diagnosis of each patient. Patients were assigned age-specific annual medical expenditures and lost wages. Model outputs included the total cumulative medical and lost productivity costs attributable to type 1 diabetes, defined as the difference in costs between patients with and without type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The model consisted of 1,630,317 patients with type 1 diabetes and an equal number of patients without type 1 diabetes. The difference in lifetime costs was $813 billion (95% confidence interval: $682\u2013$1037 billion), representing a high burden of illness compared with patients without type 1 diabetes. Sensitivity analyses demonstrated robustness in model results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings suggest significant investment in research and development of novel treatments for type 1 diabetes is justified, given the high burden of illness associated with the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2019.0398","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T10:11:22Z","timestamp":1577700682000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":84,"title":["Estimated Lifetime Economic Burden of Type 1 Diabetes"],"prefix":"10.1177","volume":"22","author":[{"given":"Matthew","family":"Sussman","sequence":"first","affiliation":[{"name":"Boston Health Economics, LLC, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Benner","sequence":"additional","affiliation":[{"name":"Boston Health Economics, LLC, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Haller","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, University of Florida, Gainesville, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Rewers","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Boston Health Economics, LLC, Boston, Massachusetts."},{"name":"Division of General Internal Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Centers for Disease Control and Prevention: Health and Economic Costs of Chronic Diabetes . National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP): About Chronic Diseases . Published February 2019. https:\/\/www.cdc.gov\/chronicdisease\/about\/costs\/index.htm (accessed December4 2018)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9017"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.529651"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.16.1873"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.0327"},{"key":"e_1_3_4_7_2","unstructured":"Waidmann TA Ormond BA Spillman BC : Potential Savings through Prevention of Avoidable Chronic Illness among CalPERS State Active Membrs . The Urban Institute Health Policy Center. 2012. https:\/\/www.urban.org\/sites\/default\/files\/publication\/25311\/412550-potential-savings-through-prevention-of-avoidable-chronic-illness-among-calpers-state-active-members.pdf (accessed December14 2018)."},{"key":"e_1_3_4_8_2","unstructured":"Fitch K Iwasaki K Pyenson B: The Cost and Quality Gap in Diabetes Care: An Actuarial Analysis. New York: Milliman Inc; 2012."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1340-P"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1379"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.05.011"},{"key":"e_1_3_4_12_2","unstructured":"McDermott J Levine B Brown A: FDA Approves Medtronic MiniMed 670G Hybrid Closed Loop for 7\u201313 Year Olds. diaTribe Learn. Published July 13 2018. https:\/\/diatribe.org\/fda-approves-medtronic-minimed-670g-hybrid-closed-loop-7-13-year-olds (accessed May3 2019)."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0126"},{"key":"e_1_3_4_14_2","unstructured":"Biniek JF Johnson W: Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices. Health Care Cost Institute; 2019:1\u201313. https:\/\/healthcostinstitute.org\/images\/easyblog_articles\/267\/HCCI-Insulin-Use-and-Spending-Trends-Brief-01.22.19.pdf (accessed May3 2019)."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1118"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-015-0009-1"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.1115"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2016.0134"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2010.11.010"},{"key":"e_1_3_4_20_2","unstructured":"Diabetes Prevention Programs: Effectiveness and Value\u2014Final Evidence Report and Meeting Summary. Institute for Clinical and Economic Review. 2016. https:\/\/icer-review.org\/material\/final-report-dpp (accessed March12 2019)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2013.04.017"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2484"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011501"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X09353946"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e31829ef01a"},{"key":"e_1_3_4_26_2","unstructured":"US Census Bureau: National State and Puerto Rico Commonwealth Totals Datasets: Population Population Change and Estimated Components of Population Change. Census.gov 2016. www.census.gov\/2017\/demo\/popest\/nation-total.html (accessed August25 2017)."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610187"},{"key":"e_1_3_4_28_2","unstructured":"Secrest AM Washington RE Orchard TJ: Diabetes in America 3rd ed. In: Cowie CC Casagrande SS eds. National Institutes of Health. Bethesda MD; 2018."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.7.1138"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1162"},{"key":"e_1_3_4_31_2","first-page":"1","article-title":"United States life tables, 2014","volume":"66","author":"Arias E","year":"2017","unstructured":"Arias E, , Heron M, , Xu J: United States life tables, 2014. Natl Vital Stat Rep, 2017; 66:1\u201364.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_4_32_2","unstructured":"Medical Expenditure Panel Survey (MEPS): Agency for Healthcare Research and Quality Rockville MD.. 2018. www.ahrq.gov\/data\/meps.html (accessed February10 2017)."},{"key":"e_1_3_4_33_2","unstructured":"Bureau of Labor Statistics Data (BLS): https:\/\/data.bls.gov\/timeseries\/CUUR0000SA0L1E?output_view=pct_12mths (accessed February10 2017)."},{"key":"e_1_3_4_34_2","unstructured":"American Diabetes Association (ADA): Statistics About Diabetes. www.diabetes.org\/diabetes-basics\/statistics (accessed March21 2019)."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.1.15"},{"key":"e_1_3_4_36_2","unstructured":"NHE Fact Sheet: December 2019. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/NHE-Fact-Sheet (accessed December13 2019)."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157832"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000308"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2013.0623"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.3.476"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2019.0398","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2019.0398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2019.0398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:12:33Z","timestamp":1777399953000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2019.0398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1089\/dia.2019.0398"],"URL":"https:\/\/doi.org\/10.1089\/dia.2019.0398","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]}}}